ESMO Real World Data and Digital Oncology最新文献

{"title":"Cancer prevalence and care disparities among individuals with intellectual disabilities: a cross-sectional pan-cancer analysis","authors":"T. Sappok ,&nbsp;M.-L. Rosenbusch ,&nbsp;R. Hering ,&nbsp;M. Schulz ,&nbsp;C. Kowalski ,&nbsp;N.T. Sibert ,&nbsp;T. Seufferlein ,&nbsp;A.W. Berger","doi":"10.1016/j.esmorw.2025.100160","DOIUrl":"10.1016/j.esmorw.2025.100160","url":null,"abstract":"<div><h3>Background</h3><div>People with intellectual disability (ID) face considerable health disparities, with cancer being among the most frequent causes of premature death. A systematic analysis of the health care situation is necessary to further strengthen treatment and support for this highly vulnerable population.</div></div><div><h3>Patients and methods</h3><div>In this cross-sectional study we analysed nationwide German outpatient health insurance data of 437 802 people with ID, which were compared to an age-, sex-, and district code-matched sample of people without ID.</div></div><div><h3>Results</h3><div>Overall, people with ID (4.2% with cancer) showed lower odds ratios for a cancer diagnosis compared with the matched cohort without ID (5.1% with cancer) [C00-C97: odds ratio 0.83; 95% confidence interval 0.82-0.84; <em>P</em> &lt; 0.0001]. Neoplasms of skin, gastrointestinal tract, and genital organs were most prevalent. People with ID less often attended cancer screening programs (OR 0.74; 0.74-0.75; <em>P</em> &lt; 0.0001). Neoplasms of the brain, testicles, ovary, uterine body, and myeloid leukaemia occurred more often in people with ID (all <em>P</em> &lt; 0.0001), while skin neoplasms, prostate cancer, tumours of the respiratory system, and breast cancer occurred less often (all <em>P</em> &lt; 0.0001). People with ID and cancer were less often treated by specialists than matched controls.</div></div><div><h3>Conclusions</h3><div>Difficulties in accessing the health care system and lower cancer screening rates may contribute to fewer cancer diagnoses. Our findings highlight specific cancer types—notably brain cancer, leukaemia, testicular and ovarian tumours—that show higher prevalence in individuals with ID compared with individuals without ID. These data underscore the increased vulnerability of the ID population to these particular malignancies, guiding future research, patient care, and screening efforts.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100160"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing breast cancer research through real-world data from the Singapore Joint Breast Cancer Registry","authors":"F.Y. Wong ,&nbsp;B.J.G. Chua ,&nbsp;R. Dent ,&nbsp;M. Hartman ,&nbsp;G.H. Lim ,&nbsp;S.Z. Lim ,&nbsp;S.H. Lim ,&nbsp;J.M. Li ,&nbsp;J.Y.Y. Ngeow ,&nbsp;W.S. Ong ,&nbsp;P. Nitar ,&nbsp;M. Preetha ,&nbsp;Y.R. Sim ,&nbsp;E.Y. Tan ,&nbsp;H.Q. Tan ,&nbsp;T.J. Tan ,&nbsp;B.K-T. Tan ,&nbsp;Q.T. Tan ,&nbsp;S.Y. Tan ,&nbsp;S-M. Tan ,&nbsp;Zewen Zhang","doi":"10.1016/j.esmorw.2025.100159","DOIUrl":"10.1016/j.esmorw.2025.100159","url":null,"abstract":"<div><h3>Background</h3><div>The Joint Breast Cancer Registry (JBCR) was established to collect comprehensive real-world data on patients with breast cancer treated across multiple institutions in Singapore. We present an overview of the registry, its structure, processes, and research findings.</div></div><div><h3>Patients and methods</h3><div>JBCR includes all breast cancer patients aged <span>≥</span>21 years old, treated in Singapore from 1980 onwards. Information on patient demographics, tumour characteristics, treatment, toxicity, and clinical outcomes is collected. We integrate data collection into clinical workflows, use automation, such as text-mining, and implement quality control processes to improve the accuracy and completeness of the registry. We further describe data security and governance processes that safeguard patients<span>’</span> privacy and allow for data sharing for research purposes.</div></div><div><h3>Results</h3><div>A diverse cohort of over 35 000 patients have been enrolled in the registry from participating institutions across Singapore. The median age at diagnosis is 54 years with a median follow-up time of 7.6 years. About a quarter of the 8883 deaths were attributed to breast cancer. Analyses of JBCR data have revealed findings such as the impact of tumour subtypes on survival, disparities in treatment responses, and the novel role of radiomics in predicting chemotherapy response. We have also identified significant ethnic and socioeconomic disparities in breast cancer outcomes, emphasizing the need for targeted interventions.</div></div><div><h3>Conclusion</h3><div>By leveraging real-world data, JBCR provides insights into the treatment trends and long-term outcomes of breast cancer in Singapore. We provide value to various stakeholders in clinical care, research, and policy-making. Future initiatives seek to address current limitations, including expanding the collection of genetic and molecular data, increasing patient-reported quality-of-life measures, and enhancing international collaborations.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100159"},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144364750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis","authors":"C. van Marcke ,&nbsp;K. Pogoda ,&nbsp;H. Fenton ,&nbsp;M. Vallet ,&nbsp;G. Plavc ,&nbsp;M. Borges ,&nbsp;H. Yousuf ,&nbsp;E. Dumas ,&nbsp;M. Berliere ,&nbsp;G. Ciliberto ,&nbsp;F.P. Duhoux ,&nbsp;V. Fano ,&nbsp;P. Hall ,&nbsp;K. Kolenc Mokotar ,&nbsp;L. Lopes Conceicao ,&nbsp;F. Pereira ,&nbsp;A. Škoporc ,&nbsp;A. Thomas ,&nbsp;G. Tramonti ,&nbsp;M.R. van Bockstal ,&nbsp;E. Krasniqi","doi":"10.1016/j.esmorw.2025.100158","DOIUrl":"10.1016/j.esmorw.2025.100158","url":null,"abstract":"<div><h3>Background</h3><div>Reduction of paclitaxel dose intensity (PDI) is frequent during neoadjuvant treatment of high-risk early triple-negative (TN) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), due to toxicity. The association between PDI and cancer outcomes is uncertain.</div></div><div><h3>Patients and methods</h3><div>We collected across eight European cancer centers (DigiCore consortium) a cohort of early TN and HER2-positive BC patients who received neoadjuvant anthracyclines and weekly paclitaxel. For each subtype, we assessed whether a threshold of reduced PDI (through dose reduction, treatment delay or early cessation) was associated with reduced pathological complete response (pCR) rate. We then described the association between reduced PDI, invasive BC-free survival (IBCFS), and overall survival.</div></div><div><h3>Results</h3><div>We included 514 TNBC and 249 HER2-positive BC patients. PDI reductions were required in 82.9% and 63.9% of patients, respectively. The optimal cut-off separating high and low PDI was 69% and 72%, respectively. Low PDI was in TNBC (29.8% of patients), but not in HER2-positive BC (22.1% of patients), significantly associated with a reduced pCR rate, compared with high PDI (37.3% versus 55.1%) (odds ratio 0.48, 95% confidence interval 0.33-0.71, <em>P</em> &lt; 0.001). In TNBC, the estimated IBCFS at 36 months was 77.9% in the PDI-low and 89.2% in the PDI-high group (hazard ratio 2.19, 95% confidence interval 1.29-3.73, <em>P</em> = 0.004).</div></div><div><h3>Conclusions</h3><div>Reduction of PDI is frequently required during neoadjuvant treatment in early TNBC and HER2-positive BC, and is associated with lower pCR rate and IBCFS in TNBC. Reduction of PDI needs careful consideration, balancing adverse events and potential impact. Confirmation in independent datasets is warranted.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100158"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic curation and analysis of ovarian cancer data across multiple electronic record systems held within the UK National Health Service: a tertiary referral centre experience","authors":"A. Samani ,&nbsp;G. Giannone ,&nbsp;L. Mercuri ,&nbsp;R. Jiang ,&nbsp;Y. Nadkarni ,&nbsp;A. Chadha ,&nbsp;E. Xing ,&nbsp;S. Ghaem-Maghami ,&nbsp;J. Krell ,&nbsp;D. Lyons ,&nbsp;C. Fotopoulou ,&nbsp;D. Papadimitriou ,&nbsp;B. Glampson ,&nbsp;E. Mayer ,&nbsp;I. McNeish ,&nbsp;L. Tookman","doi":"10.1016/j.esmorw.2025.100150","DOIUrl":"10.1016/j.esmorw.2025.100150","url":null,"abstract":"<div><h3>Background</h3><div>Manual curation of real-world data (RWD) for patients with ovarian cancer is complex and costly. We set up a novel collaboration between informatics and clinical teams generating automated data curation at scale. This enabled integrated and timely access to RWD across all ovarian cancer patients treated within a tertiary gynaecological cancer centre of the UK National Health System, setting the basis for research and operational use.</div></div><div><h3>Materials and methods</h3><div>The collaboration defined high-yield, accessible data which were pulled into tables representing various clinical domains followed by a systematic integration, cleaning and analysis within the iCARE Secure Data Environment.</div></div><div><h3>Results</h3><div>We curated data for 1581 patients diagnosed between 1 January 2014 and 31 December 2022. We showed that referrals to the specialist tumour board consistently increased over time while baseline characteristics did not change significantly. The number of patients receiving a new line of therapy decreased in 2020, the first year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak. Data robustness was supported using multivariate survival modelling demonstrating the expected impact of known prognostic factors. There was a paucity of available data for some variables (e.g. ethnicity) while others lacked a consistent storage mechanism within source systems (genomic data).</div></div><div><h3>Conclusions</h3><div>Automated curation and analysis of RWD is possible at scale, in real time. Analysis yielded clinical findings consistent with the prevalent literature and showed evolution of treatment practice. While not all unstructured data could be explored, we demonstrate that automated curation of clinically important real-world variables is feasible and can yield robust data for both research and operational purposes.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100150"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer☆","authors":"E. Arnaud ,&nbsp;P. Vaflard ,&nbsp;L. Escalup ,&nbsp;T. Ramtohul ,&nbsp;D. Meziani ,&nbsp;L. Thibault ,&nbsp;R.-P. Desmaris ,&nbsp;J.-G. Feron ,&nbsp;J.-Y. Pierga ,&nbsp;L. Cabel ,&nbsp;F. Lerebours ,&nbsp;D. Loirat ,&nbsp;P. Cottu","doi":"10.1016/j.esmorw.2025.100157","DOIUrl":"10.1016/j.esmorw.2025.100157","url":null,"abstract":"<div><h3>Background</h3><div>Pembrolizumab-based neoadjuvant chemoimmunotherapy (CIT) is the new standard of care for high-risk early triple-negative breast cancer (eTNBC). The addition of multiple cytotoxic drugs can lead to cumulative toxicities. We report the evolution of chemotherapy (CT) practice and its impact on completion and effectiveness of subsequent regimens in a real-world setting.</div></div><div><h3>Patients and methods</h3><div>We conducted an ambispective, observational study of patients with eTNBC at a comprehensive cancer centre between February 2019 and February 2024. All data were extracted from electronic health records and manually curated.</div></div><div><h3>Results</h3><div>Of the 366 patients enrolled, 247 received neoadjuvant CT and 119 received CIT. Grade 3/4 toxicities were more common in the CIT group (78.2% versus 58.6%, <em>P</em> &lt; 0.001). The most common adverse events in both groups were haematological, gastrointestinal and general health deterioration [e.g. moving from Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 to ECOG PS 2-4]. In the CIT group, 56.8% of patients experienced at least one immune-related adverse event, 11.3% of which were grade 3/4. Toxicities led to a significantly higher rate of dose reductions (48.7% versus 25.0%, <em>P</em> &lt; 0.0001), treatment delays (65.2% versus 27.5%, <em>P</em> &lt; 0.0001) or permanent discontinuation (31.1% versus 16.0%, <em>P</em> &lt; 0.001) in the CIT cohort. The pathological complete response (pCR) rate was significantly increased to 68.4% in the CIT group versus 51.9% in the CT group (<em>P</em> &lt; 0.01). No effect of toxicities or dose adjustments on the pCR rate was observed in either group.</div></div><div><h3>Conclusions</h3><div>Escalation of neoadjuvant CIT in TNBC increases toxicity and leads to significant dose reductions without affecting the improvement in pCR rate.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100157"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study","authors":"P. Barthelemy ,&nbsp;A. Thiery-Vuillemin ,&nbsp;T. Lebret ,&nbsp;P. Bigot ,&nbsp;U. Stein ,&nbsp;L.M. Dourthe ,&nbsp;R. Longo ,&nbsp;P. Gimel ,&nbsp;B. Auberger ,&nbsp;J. De La Cruz ,&nbsp;D. Malak ,&nbsp;Z. Samia ,&nbsp;N. Texier ,&nbsp;L. Albiges","doi":"10.1016/j.esmorw.2025.100155","DOIUrl":"10.1016/j.esmorw.2025.100155","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitor-based combinations have become the standard of care for treatment-naive metastatic renal cell carcinoma <strong>(</strong>mRCC). Tyrosine kinase inhibitor (TKI) monotherapy, however, may remain an option particularly for patients with a favourable International Metastatic Database Consortium (IMDC) risk.</div></div><div><h3>Material and methods</h3><div>APOLON is a non-interventional, multicentric prospective study with mRCC patients receiving frontline pazopanib treatment, designed to assess progression-free survival (PFS), overall survival (OS), objective response rate, tolerability, and subsequent post-pazopanib therapy sequences.</div></div><div><h3>Result</h3><div>The 217 patients were 71.0% male, with a median age of 69.6 years, an Eastern Cooperative Oncology Group performance status ≥2 in 17.6%, and mRCC with a favourable (27.1%), intermediate (52.1%) or poor (20.8%) IMDC score. Metastases were mainly located in lung (64.1%), bone (28.6%), mediastinal (18%)/abdominal (17.1%) lymph nodes. Median PFS was 10.6 months [95% confidence interval (CI) 9-12.5 months], similarly in patients aged &lt;65 years with PFS 11.3 months (95% CI 6.8-16.1 months) and aged ≥65 years with PFS 10.1 months (95% CI 9.0-12.4 months). The median PFS was 17.1 months (95% CI 9.9-23.2 months), 12.5 months (95% CI 9.0-15.4 months) and 6.2 months (95% CI 3.5-9.5 months) in patients with a favourable, intermediate, and poor IMDC score, respectively. The median OS was 29.1 months (95% CI 24.3-41.3 months). Objective response rate was 48.3% with a complete response in 6 (3.5%) and a partial response in 77 patients (44.8%). Grade 3/4 adverse events were reported in 45.8% of patients. No safety signals were newly identified.</div></div><div><h3>Conclusion</h3><div>The APOLON study confirmed pazopanib effectiveness and safety in patients with mRCC in a real-world setting. The efficacy remained significant in patients aged ≥65 years and was highly associated with the risk score.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"9 ","pages":"Article 100155"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort","authors":"G. George ,&nbsp;M. Rowley ,&nbsp;A.C.C. Coolen ,&nbsp;A. Santa Olalla ,&nbsp;N. Hammar ,&nbsp;M. Feychting ,&nbsp;S.N. Karagiannis ,&nbsp;D. Enting ,&nbsp;M. Van Hemelrijck","doi":"10.1016/j.esmorw.2025.100156","DOIUrl":"10.1016/j.esmorw.2025.100156","url":null,"abstract":"<div><h3>Background</h3><div>Elevated post-diagnosis levels of C-reactive protein (CRP) and haptoglobin, and low albumin levels, have been associated with poor prostate cancer (PCa) prognosis. Advanced techniques are needed for biomarker-based cancer risk prediction. We evaluated PCa risk using Cox models and risk signature analysis in the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort.</div></div><div><h3>Materials and methods</h3><div>AMORIS includes biomarker data on &gt;800 000 individuals from 1985 to 1996 in primary care and occupational setting, linked to national health and population registers through 2020. PCa risk was analysed using Cox proportional hazard models for albumin, CRP, haptoglobin and white blood cells at the third time point, adjusting for age, socioeconomic status, education level, Charlson comorbidity index (CCI) and cancer history, and risk signature analysis with training and validation sets (preventing overfitting) including repeated biomarker measurements, covariate interactions and baseline factors. Sensitivity analysis categorised age and CCI.</div></div><div><h3>Results</h3><div>Cox model showed elevated CRP and CCI ≥2 significantly increased PCa risk, with age consistently predictive. Risk signatures confirmed age as the dominant risk factor (hazard ratio 1.15 per year, 95% confidence interval 1.13-1.18) and highlighted interaction effects: younger men with cancer history had higher PCa risk, while elevated CRP with high CCI amplified risk, demonstrating strong predictive accuracy (receiver operating characteristic area under the curve: 0.82; Harrell’s C: 0.72). Categorising age and CCI further refined risk stratification.</div></div><div><h3>Conclusion</h3><div>Although elevated CRP was associated with higher PCa risk, no clear associations were detected for other markers. Advanced risk analysis found age to be the sole predictor, indicating conventional methods may overestimate biomarker roles in PCa prediction.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"8 ","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editoiral Board","authors":"","doi":"10.1016/S2949-8201(25)00056-6","DOIUrl":"10.1016/S2949-8201(25)00056-6","url":null,"abstract":"","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"8 ","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144290811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal identification of a rare head and neck cancer patient cohort in the clinical data warehouse of Greater Paris Teaching Hospital","authors":"A. La Rosa ,&nbsp;M. Verdoux ,&nbsp;P. Riebler ,&nbsp;I. Lolli ,&nbsp;C. Daniel ,&nbsp;X. Tannier ,&nbsp;S. Atallah ,&nbsp;B. Baujat ,&nbsp;E. Kempf","doi":"10.1016/j.esmorw.2025.100151","DOIUrl":"10.1016/j.esmorw.2025.100151","url":null,"abstract":"<div><h3>Background</h3><div>Ten percent of head and neck cancers (HNCs) differ from the common upper aerodigestive tract squamous-cell carcinoma. These rare HNCs can be rare because of their histology or anatomical location. The federation of clinical data warehouses (CDWs) holds potential for advancing our understanding of these pathologies. This study aimed to develop a multimodal algorithm to identify rare HNC patients in a CDW.</div></div><div><h3>Materials and methods</h3><div>We carried out a cross-sectional study on the CDW of a conglomerate of 38 university hospitals. We developed a multimodal classification algorithm to identify rare HNC patients by integrating International Classification of Diseases, 10th revision (ICD-10) codes, Association for the Development of Computer Science in Cytology and Pathological Anatomy (ADICAP) codes and free-text data from pathology reports using natural language processing (NLP). Algorithm performance was evaluated by an HNC medical expert using a validation set of 100 manually annotated cases.</div></div><div><h3>Results</h3><div>Of 333 852 cancer patients, 9141 were identified as HNC patients based on ICD-10 and ADICAP codes. The multimodal algorithm using ICD-10 or ADICAP codes or NLP-processed free text classified 4515 patients as rare HNC patients, with 2168 identified by a minimum of two data sources. It showed a 91% sensitivity and a 95% specificity when relying on multiple data sources, with a 76% positive predictive value observed for rare histology identification compared with 43% for rare topography.</div></div><div><h3>Conclusions</h3><div>This study demonstrates the feasibility and utility of a multimodal electronic health record-based approach to identify rare HNC patients in a CDW. Incorporating free-text and structured data improves the reliability of such cohort identification.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"8 ","pages":"Article 100151"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands","authors":"M.A.G. Elferink ,&nbsp;F.N. van Erning ,&nbsp;F.C. Sijtsma ,&nbsp;L.B. Valkenburg-van Iersel ,&nbsp;M.L. Wumkes ,&nbsp;J.M.L. Roodhart ,&nbsp;G.R. Vink","doi":"10.1016/j.esmorw.2025.100153","DOIUrl":"10.1016/j.esmorw.2025.100153","url":null,"abstract":"<div><h3>Background</h3><div>Insight into real-world treatment patterns in daily practice of patients with metastatic colorectal cancer (mCRC) is limited. Aim of this population-based study is to provide an overview of treatment and overall survival (OS) of patients with mCRC and to compare differences in treatment between synchronous and metachronous mCRC.</div></div><div><h3>Method</h3><div>All patients with mCRC of whom the primary tumour was diagnosed in the first half of 2015 were selected from the Netherlands Cancer Registry. Data regarding subsequent treatments were collected in 2019. Treatment patterns were compared between patients with synchronous and metachronous mCRC. OS was analysed using the Kaplan–Meier method.</div></div><div><h3>Results</h3><div>In total, 1532 patients with synchronous mCRC and 870 patients with metachronous mCRC were included. Patients with metachronous mCRC more often underwent local treatment of distant metastases (<em>P</em> &lt; 0.001). Approximately half of the patients received systemic treatment (ST) after diagnosis of mCRC, with small differences in type of ST between synchronous and metachronous mCRC. Oxaliplatin- and irinotecan-containing regimens were the predominant first- and second-line systemic therapies, respectively. Median OS of all patients with mCRC was 16.0 months [95% confidence interval (CI) 15.0-17.0 months]. Median OS from the start of each subsequent treatment line was 16.3 months (95% CI 15.5-17.5 months) for patients who started first-line ST, 8.9 months (95% CI 8.3-9.7 months) for patients who started second-line ST and 6.1 months (95% CI 5.4-6.7 months) for patients who started third-line ST.</div></div><div><h3>Conclusions</h3><div>Real-world data offer valuable insights for mCRC patients in everyday clinical practice, enabling clinicians to provide more informed guidance to their patients.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"8 ","pages":"Article 100153"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}